ECO ANIMAL HEALTH GROUP PLC

Regulatory Filings • Feb 6, 2024

National Storage Mechanism | Additional information

RNS Number : 0924C

Eco Animal Health Group PLC

06 February 2024

06 February 2024

ECO Animal Health Group plc

("ECO" or the "Company")

Trademark Approval for ECOVAXXIN® family in the EU

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, is pleased to announce that the ECOVAXXIN® trademark has been approved by the European Union ("EU").

In addition to this EU trademark ECOVAXXIN® has also been registered in the USA and in the UK, giving extensive protection in key markets for animal health products.

The registration for ECOVAXXIN® provides trademark branding for a family of vaccine products. ECOVAXXIN® is a master trademark and will protect all ECO's forthcoming vaccine products. Starting in 2025, the Company plans to market its vaccine products in multiple jurisdictions, with multiple planned launches over the next ten year period.

The first two planned products to carry the trademark will be the Company's poultry mycoplasma vaccines, specifically ECOVAXXIN® MS, a vaccine against Mycoplasma Synoviae, and ECOVAXXIN® MG, a vaccine against Mycoplasma Gallisepticum.

The trademark approval supports ECO's strategy of accelerating growth through the Company's research and development pipeline. The addition of new vaccines is expected to significantly support sales and profit growth over the next ten years.

David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "This trademark approval, complemented by registrations in the USA and the UK, provides broad protection for the ECOVAXXIN® family, fortifying our commitment to advancing growth through innovative vaccine products and supporting our strategic focus on R&D-driven expansion at ECO Animal Health Group plc."

-Ends-

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)	020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher	020 7496 3000
Investec (Joint Broker) Gary Clarence Lydia Zychowska	020 7597 5970
Equity Development Hannah Crowe Matt Evans	020 7065 2692
ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700 ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATAMLTMTIMBAI